Pasithea stockholders approve 5x increase in authorized common stock and 7x expansion of incentive plan

Pasithea Therapeutics Corp.

Authorized common stock increased from 100M to 500M shares via certificate amendment filed Jan 28, 2026.
2023 Stock Incentive Plan share reserve raised from 2,014,221 to 14,000,000 shares (increase of 11,985,779).
Proposal 1 (share increase) passed with 16,066,757 votes for vs 647,972 against; Proposal 2 passed with 8,168,126 for vs 4,550,855 against.
Board adopted plan amendment on Dec 18, 2025; stockholder approval obtained at Jan 28, 2026 special meeting.
Expanded authorized shares and equity plan provide flexibility for future capital raising and employee incentives.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Pasithea Therapeutics Corp.: Increased authorized shares of Common Stock from 100,000,000 to 500,000,000 (effective 2026-01-28).

Change: charter amendment
Effective: 2026-01-28

Exact text from the filing

On January 28, 2026, the Company filed a Certificate of Amendment (the “Certificate of Amendment”) to the Company’s Second Amended and Restated Certificate of Incorporation, as amended and/or restated from time to time (the “Certificate”), with the Secretary of State of the State of Delaware to increase the number of the Company’s authorized shares of common stock, par value $0.0001 per share (“Common Stock”), from 100,000,000 shares to 500,000,000 shares.

View on SEC.gov

Browse all governance changes →

Pasithea Therapeutics Corp. filing history →

Source: SEC EDGAR

accession 0001213900-26-008828

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.